3) That with chronic cases treatment was slow and required much larger doses of the vitamin for much longer periods of time, and many patients did not respond favourably. 4 ) That this program reduced the readmission rate and the length of admissions in subsequent relapses. 5) That the long-term prognosis was greatly improved. 6 ) That this vitamin, used as described, was relatively non-toxic, being in fact much safer than tranquillizers and antidepressants.
The following statements were incorrectly ascribed to the author and his colleagues. These were: a) That the megavitamin B-3 program would treat every schizophrenic successfully. b) That it was non-toxic. This obviously would have been a foolhardy and erroneous claim.
In two recent reports (19, 26) the side effects and toxicity of vitamin B-3 in megadoses were discussed and a clear distinction made between them. Side effects include flushing (produced by nicotinic acid only), gastrointestinal symptoms, skin reactions and headaches. It is still not clear how many of the gastrointestinal effects are due to the vitamin and how many to the vitamin filler. Cases have been described of intolerance (nausea and vomiting) to commercial nicotinic acid tablets but no such intolerance to pure nicotinic acid in gelatin capsules. Toxicity includes possible liver damage, decreases in glucose tolerance and increases in blood uric acid. In a series of over two thousand cases here there was one instance of jaundice Which developed in a nine year-old patient whenever he took nicotinic acid or nicotinamide but not when he took inositol niacinate, which hehas been taking for several years. If he discontinues this medication visual hallucinations and other severe symptoms recur in a matter of days. The Committee on Therapy of the 499 Canad. Psychiat. Ass. J. Vol. 16 (1971) It is the responsibility of any research scientist who claims to have tested a new therapy to ensure that he is familiar with the original assertions and that he reproduces the treatment upon which the original conclusions were based.
In 1957, carefully controlled studies (double blind, single blind and others) showed that the use of megadoses of vitamin B-3 (nicotinic acid) significantly improved the results of treatment of schizophrenia (40) . Since then similar claims have been made, based upon further evidence derived from a much larger number of physicians who have used the treatment program.
These claims have been challenged; firstly, by physicians who reported informally that they could not confirm the results; but their studies were not published. It was impossible to understand why they had failed since no account was given of their patients, how the megavitamins were used, for how long or with what other medication or treatment. Secondly, a few limited aspects of this therapy have recently been studied with inconclusive results; for example, the recent report in this Journal by Ban and Lehmann (2) which is not a completed study, but only an interim report.
In order to facilitate a critical review of the entire megavitamin program and the various attempts to confirm it, the claims made will be listed. The corroborative studies will then be discussed, taking into account their claims and the treatment techniques.
The author has previously claimed: (11-28, 30-40, 44-47) 1) That the incorporation of megadoses into a treatment program, as described, much improved the results of treatment.
2) That results were best with acute schizophrenic patients. Vol. 16, No.6 American Schizophrenia Association report one other similar case in, over ten thousand patients who have taken vitamin B-3 for several years. Jaundice occurs much more frequently with standard psychiatric chemotherapy.
The effects on sugar metabolism are generally beneficial for functional hyperinsulinism and are easily controlled in· diabetics.
The effects of mild elevation of uric acid are not clinically known but could be helpful, since it has been shown that megavitamin therapy tends to increase intelligence and also to increase blood uric acid levels. The vitamin has been given to patients suffering from gout whose symptoms were not aggravated and it did not interfere with their specific treatment for gout.
There are no reports of suicide from vitamin B-3. One patient here took 100 grams one afternoon -she developed some abdominal pain but no other changes.
The megavitamin program, as practised here for over three years, is a comprehensive one in which failure is not admitted until the patient has been on the therapy for five years. The cases with favourable prognosis are started on vitamins only and, depending upon their progress, the dose is increased, other chemotherapy added, other vitamins used and in cases where response is inadequate in a few months, they are given ECT.
For the information of any psychiatrist wishing to reproduce this work the treatment is again outlined in this paper. So far there is no exception to the statement that every physician who has used this approach is getting similar results. The following is a quotation from a paper by Newbold (43) entitled "How One Psychiatrist Began Using Niacin." "From the very beginning of my practice in Asheville, I had a full schedule. When I began using megavitamin therapy, the other local psychiatrists reacted violently. One psychiatrist even stated that I must be mad to abandon conventional psychiatry and involve myself in something as foolish as vitamin therapy.
"But my practice never faltered. One cannot get around the fact that patients suffering from schizophrenia do very well on niacin. New physicians and psychiatrists are beginning to evaluate my work once more in terms of results."
The Megavitamin B-3 Program
Phase I
Patients with acute symptoms who are able to co-operate with therapy or who have families able to assist in therapy are started on either nicotinamide, 3 grams per day or nicotinic acid, 3 grams per day.
Patients under twenty-one are started on nicotinamide; those over twenty-one may be started on either. If nicotinic acid is used patients must be forewarned about the flush. Sometimes ascorbic acid, 3 grams per day is used in order to reduce frequency and severity of viral infections, which are dangerous for schizophrenics. Patients are also advised to follow a good nutritional program with restriction of sucrose and sucrose-rich foods. On the first recheck if patients have improved (usually the first decision is made in one month) they are maintained on the program. If progress is too slow or if the severity of symptoms is such that more rapid control is required they are then given any of the current chemotherapies used in psychiatry. Progress is charted by means of clinical evaluation plus the Hoffer-Osmond Diagnostic Scales (HOD) (30, 42) .
Phase II
Patients unable to follow this regime must usually be admitted to hospital where they will receive a series of bilateral or unilateral ECTs plus appropriate chemotherapy. Their average stay in hospital is about two weeks (29) . The dose range of nicotinic acid is 3 to 30 grams per day with a mode of 6 to 9 grams. The dose range of nicotinamide is 3 to 9 grams with the most common dosage being 3 to 6 grams. The usual tranquillizers and/ or antidepressants are used in effective doses plus any other indicated chemotherapy.
As soon as the patients have gained some stability they are discharged and continued on outpatient therapy. Chronic patients who have not responded sufficiently may be brought back at intervals of six to twelve months for another brief series of ECT, and this will be continued for at least five years. Patients who recover are not followed routinely but will usually return if they relapse.
Attempts at Corroboration -Negative
Greenbaum (10) compared the effect of nicotinamide, 1 gram per 50 pounds body weight for six months with and without a tranquillizer, . with placebo. The patients were schizophrenic children between the ages of four and twelve. The clinical evaluation before and after treatment included a structural play period, a draw-a-man task and an instructural free play opportunity. Speech and performance were assessed, using a portion of the Wechsler Intelligence Test for children and the Sequin Form Board Test.
The results are very difficult to interpret: the niacin group improved 40 units, the placebo group 26 units and the niacin-tranquillizer group did not improve significantly. With respect to the number of words spoken before and after, again the niacin group showed the greatest gain (1.18) followed by placebo and then niacin plus tranquillizer. Enthusiastic claims by parents of improvement in children were discounted because they were made in some cases for children who were receiving placebo, but no numbers were given. Unfortunately, Dr. Greenbaum's study does not replicate any of ours.
H has been pointed out that children who were negative for malvaria are not likely to respond to Vitamin B-3. To test this the author has carried out a double blind controlled experiment. In a current controlled study which is sponsored by the Canadian Mental Health Association, Saskatchewan Division, nearly 50 per cent of disturbed children are positive, and this suggests that their assay was faulty. The mauve factor is kryptopyrrole (41) .
The reasons for their failure to confirm were probably due to an inadequate dose, a too heavy use of tranquillizers and too brief a period of therapy. The recommended dose for children is 3 to 6 grams per day combined with minimal doses of tranquillizers, for example, 10 milligrams of thioridazine, t.i.d. or with stimulants such as methylphenidatet and deanol.tt On the contrary, Green (7, 8, 9) , using recommended doses, found highly significant responses in disturbed children. They responded so quickly to nicotinamide that he considered them to be cases of subclinical pellagra. Most of these children suffered major perceptual changes which shaded into those found in childhood schizophrenia.
Rimland reported a controlled study of one hundred and ninety schizophrenic and autistic children treated with megavitamins. Most had already failed to respond to a large number of psychoactive drugs. He states, "In view of the disappointment the parents have so often experienced with earlier chemotherapy, one might almost postulate a negative placebo effect, where no improvement is the most expected effect." (50) In a single blind study now being conducted on more than thirty disturbed children, the dosage is 3 to 6 grams of nicotinamide, 3 grams of ascorbic acid and the occasional use of small doses of tranquillizers. Children on tranquillizers have great difficulty in learning, even though there is symptomatic control, and therefore these drugs are discontinued as quickly as possible. In this design, as soon as the children have recovered (this requires between three to eighteen months) they are placed on placebo pills, identical in appearance with nicotinamide, but they are maintained on ascorbic acid.· The mothers know of the change but the children do not. Recovery is determined by clinical evaluation, parents' reports and school performance records. So far over fifteen children have gone through a placebo phase. Most of them relapsed Ritalin: Ciba.~D eaner: Riker.
within one month and one in three months. When . nicotinamide was again started, all the children responded as before, but more slowly.I Similar results have been reported by Cott and Hawkins. An example is a report by Foy (6) who describes the recovery of her schizophrenic son who was a patient of Dr. Cott (3, 4, 5) .
Ananth, Ban, Lehmann and Bennett (1) found significant improvement in a small group of chronic schizophrenics given 3 grams of nicotinic acid per day over 14 weeks, using a double blind placebo-controlled cross over study. It did not prevent exacerbation of the psychosis produced by administration of large doses of methionine and tranylcypromine.
In a second report Ramsay, Ban, Lehmann, Saxena and Bennett (48) divided thirty acute patients, all receiving tranquillizers, into three groups;" they received, respectively, placebo, nicotinamide and nicotinic acid (3 grams a day for six months). No significant difference was found among the groups, which is not surprising as nearly every patient improved (29) .
It has never been claimed that nicotinic acid when administered first would improve discharge rates or shorten the duration of stay in hospital during a first admission, but it has been claimed that there is a decrease in the readmission rates, especially if treatment is continued after discharge, and that the duration of subsequent admissions is shortened.
There have been no other published studies and therefore it is obvious that only bits and pieces of this program have been tested. It is hoped that investigators will one day start with a cohort of schizophrenics and carry them through the entire procedure together with a control cohort who would not receive any vitamins. In this way improvement with megadoses of vitamin B-3 would be apparent within two years. §This study by the author is not yet published.
:t:URoniacol -Hoffmann-La Roche.
Errors in Design Leading to Lack of Confirmation
Many reasons have accumulated to explain the lack of corroboration -these are listed and illustrated: 1) Using the wrong substance without knowing that it is not nicotinic acid -Rapp (49) reported that butapyridyl carbinolrtt did not benefit alcoholics. He used the double blind design, but butapyridyl carbinol is not a vitamin (or has only minimal vitamin quantities) and there have been no claims that it helps alcoholics.
2) Using tablets which had such small quantities of the vitamin that the enormous number required prevented continuation of the study -patients in a California State Hospital recently refused to take the 30 tablets per day required for the absorption of the necessary 500-1000 mg. of the vitamin which was administered in 100 mg. tablets. In addition, these tablets contain so much inert filler (which may produce nausea with lactose) that the sheer bulk throws an unnecessary burden on the gastrointestinal tract.
3) Using a dosage which is too low and for too brief a period -in 1958 a psychiatrist reported at a meeting that he had given 1 gram per day for seven days to twelve of the most deteriorated patients in a Minnesota State Hospital. This statement was not published but he had purported to prove that nicotinic acid was of no benefit in schizophrenia. At that time it had been recommended that there should be a minimum trial of 30 days using 3 grams per day in acute cases only, combined with BCT in most cases. It was not recommended for chronic cases.
There have been numerous patients receiving 100 mg., t.i.d, from physicians who believed they were using the megavitamin therapy. The prescription was often correct but the pharmacist, believing it to be an error and not having 500 mg. tablets, dispensed 50 mg. instead. 4) Tranquillizers being stopped before the vitamin B-3 is able to exert its effectthere have been many histories of patients who relapsed when their tranquillizers were stopped at the time of commencement of the vitamin therapy, and the patient and his family were often told that the vitamins had had no effect and in fact caused the relapse. 5) Discontinuing megadoses of vitamin B-3 too soon -several patients who had recovered moved to other parts of Canada where they informed their new physicians of their medication. In most cases this medication was maintained but a minority were told that the vitamin was dangerous and/ or of no value and when these patients stopped taking their medication they became psychotic again within months.
Some physicians have made no attempt to deal with the minor side effects which are usually transient, but have instead discontinued the medication.
A few patients who have been admitted to hospital for physical illnesses were refused continuance of their vitamin B-3 therapy, and consequently had become psychotic again by the time they were discharged.
However, the main reason for failure to corroborate the claims for megavitamin treatment. is that the program has not been properly followed, and unless this is done it is illogical for investigators to draw any conclusions based on their own research.
